Chronic hepatitis B virus infection

This phase 2 trial is testing whether a combination of two experimental drugs, BRII-835 and BRII-179, can clear the hepatitis B virus from the body in adults with chronic infection. Participants will receive the drug combination and then be monitored to see if they can safely sto…

This early-stage trial tested a new two-part vaccine designed to treat chronic hepatitis B. It involved 26 healthy adults to check safety and immune response. The vaccine uses a protein first shot followed by a booster to teach the immune system to attack the virus.

This study tests a drug called hydronidone in 300 adults with liver scarring (fibrosis or cirrhosis) from chronic hepatitis B. Participants take the drug three times daily for 28 days to see if it is safe. The main goal is to track any side effects.

This study tests a drug called hydronidone in 200 adults with liver fibrosis caused by chronic hepatitis B or fatty liver disease. Participants take three capsules three times daily for 28 days. The main goal is to check for side effects, not to measure how well the drug works.

This study tests a drug called hydronidone in 150 adults with liver scarring caused by chronic hepatitis B. Participants take the capsules three times daily for 28 days. The main goal is to check for side effects and ensure the drug is safe. This is an early-phase trial, so it fo…

This study tests whether adults with chronic hepatitis B who have no liver scarring can safely stop taking antiviral drugs. The 140 participants have undetectable virus levels and negative HBeAg status. Researchers will monitor for viral relapse and liver problems over time.

This early-phase trial tested an experimental drug called BW-20507 in 32 people. First, healthy volunteers received a single dose to check safety. Then, people with chronic hepatitis B received multiple doses to see how the drug behaves in the body and whether it fights the virus…

This Phase 3 study tests bepirovirsen, an experimental drug, in 857 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough to allow patients to stop all hepatitis B treatments and remain viru…

This Phase 3 trial tests a drug called bepirovirsen in nearly 1,000 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough that participants can safely stop all hepatitis B medications and re…

This study tests whether the immunotherapy drug durvalumab can be safely given to people with advanced liver cancer who also have an active hepatitis B infection. All participants receive an antiviral drug (entecavir) to control the hepatitis B virus. The main goal is to see if d…

This early-stage study tested a new treatment approach for adults with chronic hepatitis B or D. Twenty participants received two medications in sequence: P1101 (a type of interferon) followed by an anti-PD1 drug. The main goal was to check safety and tolerability, while also loo…

This study tests an experimental drug called AHB-137 in healthy volunteers and people with chronic hepatitis B who are already on antiviral medication. The goal is to check if the drug is safe and shows early signs of controlling the virus. About 129 participants will receive eit…

This phase 2b trial tested a combination of two experimental vaccines (VTP-300) plus a low dose of the cancer drug nivolumab in 121 adults with chronic hepatitis B who were already on antiviral medication. The goal was to see if the treatment could significantly lower hepatitis B…

This Phase 2 study tested an experimental drug called AB-729 combined with pegylated interferon and standard antiviral pills in 43 adults with chronic hepatitis B. The goal was to see if this approach could safely lower hepatitis B surface antigen levels and allow some participan…

This study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely eliminate hepatitis B surface antigen in people with chronic hepatitis B. 244 adults with long-term infection who were already on ant…

This study tested an experimental drug called VIR-2218 in 84 adults with chronic hepatitis B. Some participants received VIR-2218 alone, and others got it combined with pegylated interferon. The main goals were to check safety and how well the drug works against the virus. The st…

This early-stage trial tests AB-101, an oral drug that blocks a protein called PD-L1 to help the immune system fight the hepatitis B virus. The study involves 128 people, including healthy volunteers and patients with chronic hepatitis B. Researchers are primarily checking for sa…

This early-stage trial tested an experimental injection called HH-006 in 36 adults with untreated chronic hepatitis B. The study aimed to check the drug's safety, how the body processes it, and whether it can lower virus levels. Participants received either HH-006 or a placebo ov…

This study tests whether a DNA vaccine can help people with chronic hepatitis B control the virus after they stop taking standard antiviral drugs. The vaccine aims to boost the immune system to delay the virus from becoming active again. The trial involves 70 adults who have unde…

This study tested the drug eltrombopag in 48 Chinese adults with chronic hepatitis B and a bleeding disorder called immune thrombocytopenia (low platelets). The goal was to see if taking eltrombopag for 6 to 22 weeks could safely raise platelet counts. The trial is complete, but …

This early-stage trial tested two experimental drugs, tobevibart and elebsiran, alone or with standard treatments, in 33 adults with chronic hepatitis B. The goal was to see if these combinations could safely suppress the virus and reduce hepatitis B surface antigen levels. The s…

This study tested a new drug called TQA3605 in 122 adults with chronic hepatitis B who still had low levels of virus despite standard treatment. Participants took either TQA3605 or a placebo alongside their usual antiviral pills for 24 weeks. The goal was to see if adding TQA3605…

This early-stage trial tested two experimental therapeutic vaccines, GS-2829 and GS-6779, in 83 healthy people and those with chronic hepatitis B. The main goal was to check safety and tolerability, while also measuring immune responses. The vaccines are designed to help the body…

This completed phase 2 study tested a two-step treatment for chronic hepatitis B. First, participants received an antisense drug (bepirovirsen) for 12 or 24 weeks, followed by a targeted immunotherapy. The goal was to see if this sequence could safely improve virus control beyond…

This study tested an experimental injection called RBD1016 in 48 adults with chronic hepatitis B who were already taking standard antiviral pills. The goal was to see if the injection could safely lower hepatitis B surface antigen (HBsAg), a marker of the virus. Participants rece…

This study tested whether adding pegylated interferon alfa-2a to standard nucleoside analogue therapy could help people with chronic hepatitis B lose the hepatitis B surface antigen (HBsAg). 119 adults with HBeAg-negative chronic hepatitis B who had been on nucleoside analogues f…

This early-stage trial tests an experimental oral drug called ALG-000184 in healthy volunteers and people with chronic hepatitis B. The main goals are to check safety, how the body processes the drug, and whether it can lower hepatitis B virus levels. Participants take the drug d…

This early-stage trial tested a DNA vaccine in 10 adults with chronic hepatitis B who had not responded to standard treatments. The vaccine was designed to train the immune system to fight the virus. The main goal was to check safety, with a secondary goal of seeing if the vaccin…

This study tested several new drug combinations in 281 people with chronic hepatitis B who were already on standard antiviral therapy. The goal was to see if adding experimental drugs could clear a key virus marker (HBsAg) from the blood. Participants received different combinati…

This study checked how well new blood tests (Access HBV assays) can detect hepatitis B infection. Researchers tested over 21,000 leftover blood samples from adults, including blood donors and hospital patients. The goal was to see if these tests are accurate compared to existing …

This early-stage trial will test a new drug called hydronidone, which is being developed for liver fibrosis caused by hepatitis B. Since patients often need to take antiviral drugs for hepatitis B, researchers want to see if hydronidone can be taken safely alongside four common a…

This study looks back at the medical records of 1,000 adults with both chronic hepatitis B and metabolic fatty liver disease. The goal is to understand how these conditions affect kidney function, especially in people on long-term antiviral therapy. Researchers will also examine …

This study tested whether people with chronic hepatitis B who had been on antiviral drugs for at least 4 years could safely stop treatment. Fifteen adults were monitored with monthly blood tests for 6 months after stopping, then every 3 months. The goal was to see if the virus st…

This study examines whether long-term use of antiviral drugs for chronic hepatitis B is linked to kidney problems in patients who also have non-alcoholic fatty liver disease. Researchers will analyze medical records from 300 patients to compare kidney function among those taking …

This study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…

This study looked at how people with chronic liver disease (like hepatitis B, C, or fatty liver) respond to COVID-19 vaccines. About 233 adults had three visits over a year to check their immune response and see if they got COVID-19. The goal was to understand if liver disease af…

This completed study looked at 274 foreign-born adults in the US with chronic hepatitis B to understand why many do not get proper follow-up care. Participants completed a one-time survey about their background, immigration experience, and healthcare access. The goal is to identi…

This completed study looked at 217 adults with chronic hepatitis B to see how common fatty liver and fatty pancreas are in obese versus lean patients. Researchers used ultrasound and a special liver stiffness test to measure fat and scarring. The goal was to learn more about how …